Redeye’s initial comment on the Q1 report was published earlier this morning.
Episurf Medical’s Q1 sales were broadly in line with our estimate, while operating expenses were sli...
After an eventful 2022, Crunchfish looks to make 2023 the year where things take off.
Vow released its Q1 2023 trading update this morning (as a reminder, the company reports semi-annual...
Redeye thinks the Q1 report was soft and that the outlook remains uncertain.
Redeye updates on Invisio following the company’s Q1-results which came in much stronger than expect...
Sales up 36% organically, and 26% better than ABGSCe At an inflection point for profitability with h...
Net sales at SEK 75.2m, above ABGSCe SEK 70.7m Circular Energy sales shine once again.
Enersense’s Q1 revenue grew clearly faster than estimated, at a rate of 39% y/y, which also helped p...
Q1 report on Thursday, 11 May Öyfjellet finally completed The share is trading at 9x P/E on '23e Q1...
Budet från Francois-Charles Oberthur Den 16 januari lämnade Francois-Charles Oberthur SAS ("FCO") et...
Q1 sales, EBIT and order intake beats, tailwinds continue We raise estimates significantly, EBIT +26...
Q-linea is in a transition period after the break with Thermo Fisher, and in Q1 there are no reporte...
I dag offentliggjorde Spotlight Group sin delårsrapport för det första kvartalet 2023.
Redeye har hunnit smälta Fas III-resultaten från den konkurrerande antikroppen Donanemab.
Vaisala delivered strong topline and solid order growth in Q1.
Q1 NOI beat drives estimates higher Another report with strong operational performance Relatively si...
Redeye thinks the Q1 report was strong and lays a solid foundation for Sivers possibility of reachin...
Redeye updates its estimates on the back of I-Tech’s Q1’23 report, delivering another significant es...
Redeye updates its estimates following Arise’s Q1 report.
